Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation
Transarterial chemoembolization (TACE) was obtained acceptable benefit for advanced hepatocellular carcinoma (HCC). Here in this study, we compared the benefit of TACE combined palliative thermal ablation with TACE alone for HCC with portal vein tumor thrombus (PVTT). Patients with HCC and PVTT were...
Gespeichert in:
| Veröffentlicht in: | International journal of hyperthermia 2022-12, Vol.39 (1), p.97-107 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 107 |
|---|---|
| container_issue | 1 |
| container_start_page | 97 |
| container_title | International journal of hyperthermia |
| container_volume | 39 |
| creator | Zhou, Qunfang An, Yongcheng Liu, Ting Liu, Zishan Li, Ruixia Wang, Chenmeng Zhou, Feng Liu, Congjuan Zhu, Kangshun |
| description | Transarterial chemoembolization (TACE) was obtained acceptable benefit for advanced hepatocellular carcinoma (HCC). Here in this study, we compared the benefit of TACE combined palliative thermal ablation with TACE alone for HCC with portal vein tumor thrombus (PVTT).
Patients with HCC and PVTT were retrospectively analyzed from January 2012 to December 2017, who accepted treatment of TACE alone (TACE group) or TACE plus palliative thermal ablation (TACE + P-ablation group). Propensity score matching (PSM) was applied to balance differences between the two groups. Overall survival (OS) and progression-free survival (PFS) rates were compared between groups.
Median follow-up time was 7.4 (3.0-60.0) months. In the cohort, 142 patients were enrolled in TACE group and 86 patients were enrolled in TACE + P-ablation group. The pre-PSM estimated 6-, 12-, and 18-month OS rates for the TACE + P-ablation group were 70.9, 46.5, and 31%, respectively, whereas rates for the TACE group were 57, 23.1, and 10%, respectively. After PSM, OS and PFS rates remained coincident with the pre-PSM. Risk factors for poor OS included PVTT type III and type II relative to type I (HR = 1.76; 95% CI, 1.13-2.74; p = .01) and (HR = 1.86; 95% CI, 1.2-2.88; p = .006), TACE alone (HR = 1.40; 95% CI, 1.01-1.96; p = .04), a single TACE treatment (HR = 2.69; 95% CI, 1.79-4.03; p |
| doi_str_mv | 10.1080/02656736.2021.2021303 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_02656736_2021_2021303</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1c52d075a5154444a87269137ef73a88</doaj_id><sourcerecordid>2616600782</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-429a17494b222b382c3cb3da61329a319313a865749d589567855ff2920ec65a3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEokPhEUBesknxv5MdqOKnUiVYwNq6cZyOK8cebKdVeSieEWcy7RIvbF37u-fI9zTNW4IvCO7wB0ylkIrJC4opOW4Ms2fNjnDJW0GEet7sVqZdobPmVc63GGMuqHrZnDHeq77jYtf8_ZHiTYjZZRQndIDibCgZ3buyR3tb62is94uHhAwk40KcAUEY0SGmAh7dWRdQWeaYUNmnOA9LRiVZKHbcREy9c6HqxrA6lAQhQyo2udpt9naOdh6id3825CgN3rta3tmqadNcQRj88f1182ICn-2b03ne_Pry-eflt_b6-9ery0_XreGqLy2nPRDFez5QSgfWUcPMwEaQhNUXRnpGGHRSVGQUXV8H2QkxTbSn2BopgJ03V5vuGOFWH5KbIT3oCE4fL2K60fUTzniriRF0xEpAHTqvCzpFZU-YspOqJl3Ver9pHVL8vdhc9OzyOlUINi5ZU0mkxFh1tKJiQ02KOSc7PVkTrNfY9WPsek1cn2Kvfe9OFssw2_Gp6zHnCnzcABemWCd6H5MfdYEHH9NUIzEua_Z_j3_m4r8h</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616600782</pqid></control><display><type>article</type><title>Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Access via Taylor & Francis (Open Access Collection)</source><creator>Zhou, Qunfang ; An, Yongcheng ; Liu, Ting ; Liu, Zishan ; Li, Ruixia ; Wang, Chenmeng ; Zhou, Feng ; Liu, Congjuan ; Zhu, Kangshun</creator><creatorcontrib>Zhou, Qunfang ; An, Yongcheng ; Liu, Ting ; Liu, Zishan ; Li, Ruixia ; Wang, Chenmeng ; Zhou, Feng ; Liu, Congjuan ; Zhu, Kangshun</creatorcontrib><description>Transarterial chemoembolization (TACE) was obtained acceptable benefit for advanced hepatocellular carcinoma (HCC). Here in this study, we compared the benefit of TACE combined palliative thermal ablation with TACE alone for HCC with portal vein tumor thrombus (PVTT).
Patients with HCC and PVTT were retrospectively analyzed from January 2012 to December 2017, who accepted treatment of TACE alone (TACE group) or TACE plus palliative thermal ablation (TACE + P-ablation group). Propensity score matching (PSM) was applied to balance differences between the two groups. Overall survival (OS) and progression-free survival (PFS) rates were compared between groups.
Median follow-up time was 7.4 (3.0-60.0) months. In the cohort, 142 patients were enrolled in TACE group and 86 patients were enrolled in TACE + P-ablation group. The pre-PSM estimated 6-, 12-, and 18-month OS rates for the TACE + P-ablation group were 70.9, 46.5, and 31%, respectively, whereas rates for the TACE group were 57, 23.1, and 10%, respectively. After PSM, OS and PFS rates remained coincident with the pre-PSM. Risk factors for poor OS included PVTT type III and type II relative to type I (HR = 1.76; 95% CI, 1.13-2.74; p = .01) and (HR = 1.86; 95% CI, 1.2-2.88; p = .006), TACE alone (HR = 1.40; 95% CI, 1.01-1.96; p = .04), a single TACE treatment (HR = 2.69; 95% CI, 1.79-4.03; p < .001), 2 or 3 TACE treatments (HR = 2.02; 95% CI, 1.32-3.09; p = .001).
The combination of TACE and palliative thermal ablation for HCC with PVTT could obtain delayed progression and longer survival.</description><identifier>ISSN: 0265-6736</identifier><identifier>EISSN: 1464-5157</identifier><identifier>DOI: 10.1080/02656736.2021.2021303</identifier><identifier>PMID: 34979845</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; Chemoembolization, Therapeutic ; Combined Modality Therapy ; Hepatocellular carcinoma ; Humans ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; palliative ; Portal Vein ; portal vein tumor thrombus ; Prognosis ; Retrospective Studies ; thermal ablation ; Thrombosis - pathology ; Thrombosis - therapy ; transarterial chemoembolization ; Treatment Outcome</subject><ispartof>International journal of hyperthermia, 2022-12, Vol.39 (1), p.97-107</ispartof><rights>2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-429a17494b222b382c3cb3da61329a319313a865749d589567855ff2920ec65a3</citedby><cites>FETCH-LOGICAL-c479t-429a17494b222b382c3cb3da61329a319313a865749d589567855ff2920ec65a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/02656736.2021.2021303$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/02656736.2021.2021303$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>315,781,785,865,2103,27504,27926,27927,59145,59146</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34979845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Qunfang</creatorcontrib><creatorcontrib>An, Yongcheng</creatorcontrib><creatorcontrib>Liu, Ting</creatorcontrib><creatorcontrib>Liu, Zishan</creatorcontrib><creatorcontrib>Li, Ruixia</creatorcontrib><creatorcontrib>Wang, Chenmeng</creatorcontrib><creatorcontrib>Zhou, Feng</creatorcontrib><creatorcontrib>Liu, Congjuan</creatorcontrib><creatorcontrib>Zhu, Kangshun</creatorcontrib><title>Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation</title><title>International journal of hyperthermia</title><addtitle>Int J Hyperthermia</addtitle><description>Transarterial chemoembolization (TACE) was obtained acceptable benefit for advanced hepatocellular carcinoma (HCC). Here in this study, we compared the benefit of TACE combined palliative thermal ablation with TACE alone for HCC with portal vein tumor thrombus (PVTT).
Patients with HCC and PVTT were retrospectively analyzed from January 2012 to December 2017, who accepted treatment of TACE alone (TACE group) or TACE plus palliative thermal ablation (TACE + P-ablation group). Propensity score matching (PSM) was applied to balance differences between the two groups. Overall survival (OS) and progression-free survival (PFS) rates were compared between groups.
Median follow-up time was 7.4 (3.0-60.0) months. In the cohort, 142 patients were enrolled in TACE group and 86 patients were enrolled in TACE + P-ablation group. The pre-PSM estimated 6-, 12-, and 18-month OS rates for the TACE + P-ablation group were 70.9, 46.5, and 31%, respectively, whereas rates for the TACE group were 57, 23.1, and 10%, respectively. After PSM, OS and PFS rates remained coincident with the pre-PSM. Risk factors for poor OS included PVTT type III and type II relative to type I (HR = 1.76; 95% CI, 1.13-2.74; p = .01) and (HR = 1.86; 95% CI, 1.2-2.88; p = .006), TACE alone (HR = 1.40; 95% CI, 1.01-1.96; p = .04), a single TACE treatment (HR = 2.69; 95% CI, 1.79-4.03; p < .001), 2 or 3 TACE treatments (HR = 2.02; 95% CI, 1.32-3.09; p = .001).
The combination of TACE and palliative thermal ablation for HCC with PVTT could obtain delayed progression and longer survival.</description><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Chemoembolization, Therapeutic</subject><subject>Combined Modality Therapy</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>palliative</subject><subject>Portal Vein</subject><subject>portal vein tumor thrombus</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>thermal ablation</subject><subject>Thrombosis - pathology</subject><subject>Thrombosis - therapy</subject><subject>transarterial chemoembolization</subject><subject>Treatment Outcome</subject><issn>0265-6736</issn><issn>1464-5157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kc1u1DAUhSMEokPhEUBesknxv5MdqOKnUiVYwNq6cZyOK8cebKdVeSieEWcy7RIvbF37u-fI9zTNW4IvCO7wB0ylkIrJC4opOW4Ms2fNjnDJW0GEet7sVqZdobPmVc63GGMuqHrZnDHeq77jYtf8_ZHiTYjZZRQndIDibCgZ3buyR3tb62is94uHhAwk40KcAUEY0SGmAh7dWRdQWeaYUNmnOA9LRiVZKHbcREy9c6HqxrA6lAQhQyo2udpt9naOdh6id3825CgN3rta3tmqadNcQRj88f1182ICn-2b03ne_Pry-eflt_b6-9ery0_XreGqLy2nPRDFez5QSgfWUcPMwEaQhNUXRnpGGHRSVGQUXV8H2QkxTbSn2BopgJ03V5vuGOFWH5KbIT3oCE4fL2K60fUTzniriRF0xEpAHTqvCzpFZU-YspOqJl3Ver9pHVL8vdhc9OzyOlUINi5ZU0mkxFh1tKJiQ02KOSc7PVkTrNfY9WPsek1cn2Kvfe9OFssw2_Gp6zHnCnzcABemWCd6H5MfdYEHH9NUIzEua_Z_j3_m4r8h</recordid><startdate>20221231</startdate><enddate>20221231</enddate><creator>Zhou, Qunfang</creator><creator>An, Yongcheng</creator><creator>Liu, Ting</creator><creator>Liu, Zishan</creator><creator>Li, Ruixia</creator><creator>Wang, Chenmeng</creator><creator>Zhou, Feng</creator><creator>Liu, Congjuan</creator><creator>Zhu, Kangshun</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20221231</creationdate><title>Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation</title><author>Zhou, Qunfang ; An, Yongcheng ; Liu, Ting ; Liu, Zishan ; Li, Ruixia ; Wang, Chenmeng ; Zhou, Feng ; Liu, Congjuan ; Zhu, Kangshun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-429a17494b222b382c3cb3da61329a319313a865749d589567855ff2920ec65a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Chemoembolization, Therapeutic</topic><topic>Combined Modality Therapy</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>palliative</topic><topic>Portal Vein</topic><topic>portal vein tumor thrombus</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>thermal ablation</topic><topic>Thrombosis - pathology</topic><topic>Thrombosis - therapy</topic><topic>transarterial chemoembolization</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Qunfang</creatorcontrib><creatorcontrib>An, Yongcheng</creatorcontrib><creatorcontrib>Liu, Ting</creatorcontrib><creatorcontrib>Liu, Zishan</creatorcontrib><creatorcontrib>Li, Ruixia</creatorcontrib><creatorcontrib>Wang, Chenmeng</creatorcontrib><creatorcontrib>Zhou, Feng</creatorcontrib><creatorcontrib>Liu, Congjuan</creatorcontrib><creatorcontrib>Zhu, Kangshun</creatorcontrib><collection>Access via Taylor & Francis (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of hyperthermia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Qunfang</au><au>An, Yongcheng</au><au>Liu, Ting</au><au>Liu, Zishan</au><au>Li, Ruixia</au><au>Wang, Chenmeng</au><au>Zhou, Feng</au><au>Liu, Congjuan</au><au>Zhu, Kangshun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation</atitle><jtitle>International journal of hyperthermia</jtitle><addtitle>Int J Hyperthermia</addtitle><date>2022-12-31</date><risdate>2022</risdate><volume>39</volume><issue>1</issue><spage>97</spage><epage>107</epage><pages>97-107</pages><issn>0265-6736</issn><eissn>1464-5157</eissn><abstract>Transarterial chemoembolization (TACE) was obtained acceptable benefit for advanced hepatocellular carcinoma (HCC). Here in this study, we compared the benefit of TACE combined palliative thermal ablation with TACE alone for HCC with portal vein tumor thrombus (PVTT).
Patients with HCC and PVTT were retrospectively analyzed from January 2012 to December 2017, who accepted treatment of TACE alone (TACE group) or TACE plus palliative thermal ablation (TACE + P-ablation group). Propensity score matching (PSM) was applied to balance differences between the two groups. Overall survival (OS) and progression-free survival (PFS) rates were compared between groups.
Median follow-up time was 7.4 (3.0-60.0) months. In the cohort, 142 patients were enrolled in TACE group and 86 patients were enrolled in TACE + P-ablation group. The pre-PSM estimated 6-, 12-, and 18-month OS rates for the TACE + P-ablation group were 70.9, 46.5, and 31%, respectively, whereas rates for the TACE group were 57, 23.1, and 10%, respectively. After PSM, OS and PFS rates remained coincident with the pre-PSM. Risk factors for poor OS included PVTT type III and type II relative to type I (HR = 1.76; 95% CI, 1.13-2.74; p = .01) and (HR = 1.86; 95% CI, 1.2-2.88; p = .006), TACE alone (HR = 1.40; 95% CI, 1.01-1.96; p = .04), a single TACE treatment (HR = 2.69; 95% CI, 1.79-4.03; p < .001), 2 or 3 TACE treatments (HR = 2.02; 95% CI, 1.32-3.09; p = .001).
The combination of TACE and palliative thermal ablation for HCC with PVTT could obtain delayed progression and longer survival.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>34979845</pmid><doi>10.1080/02656736.2021.2021303</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0265-6736 |
| ispartof | International journal of hyperthermia, 2022-12, Vol.39 (1), p.97-107 |
| issn | 0265-6736 1464-5157 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_02656736_2021_2021303 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Access via Taylor & Francis (Open Access Collection) |
| subjects | Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Chemoembolization, Therapeutic Combined Modality Therapy Hepatocellular carcinoma Humans Liver Neoplasms - pathology Liver Neoplasms - therapy palliative Portal Vein portal vein tumor thrombus Prognosis Retrospective Studies thermal ablation Thrombosis - pathology Thrombosis - therapy transarterial chemoembolization Treatment Outcome |
| title | Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T10%3A32%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognosis%20of%20patients%20with%20hepatocellular%20carcinoma%20and%20portal%20vein%20tumor%20thrombus%20treated%20with%20combination%20of%20transarterial%20chemoembolization%20and%20palliative%20thermal%20ablation&rft.jtitle=International%20journal%20of%20hyperthermia&rft.au=Zhou,%20Qunfang&rft.date=2022-12-31&rft.volume=39&rft.issue=1&rft.spage=97&rft.epage=107&rft.pages=97-107&rft.issn=0265-6736&rft.eissn=1464-5157&rft_id=info:doi/10.1080/02656736.2021.2021303&rft_dat=%3Cproquest_cross%3E2616600782%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2616600782&rft_id=info:pmid/34979845&rft_doaj_id=oai_doaj_org_article_1c52d075a5154444a87269137ef73a88&rfr_iscdi=true |